What is the intrinsic value of Novavax?
As of 2025-06-13, the Intrinsic Value of Novavax Inc (NVAX) is
14.78 USD. This Novavax valuation is based on the model Peter Lynch Fair Value.
With the current market price of 7.15 USD, the upside of Novavax Inc is
106.68%.
Is Novavax undervalued or overvalued?
Based on its market price of 7.15 USD and our intrinsic valuation, Novavax Inc (NVAX) is undervalued by 106.68%.
14.78 USD
Intrinsic Value
Novavax Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(229.68) - (52.87) |
(84.64) |
-1283.8% |
| DCF (Growth 10y) |
(96.96) - (422.08) |
(155.60) |
-2276.2% |
| DCF (EBITDA 5y) |
(26.75) - (35.32) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(54.10) - (74.39) |
(1,234.50) |
-123450.0% |
| Fair Value |
14.78 - 14.78 |
14.78 |
106.68% |
| P/E |
48.23 - 70.64 |
62.66 |
776.3% |
| EV/EBITDA |
33.11 - 52.99 |
43.96 |
514.8% |
| EPV |
(32.92) - (45.72) |
(39.32) |
-650.0% |
| DDM - Stable |
32.34 - 168.59 |
100.47 |
1305.1% |
| DDM - Multi |
(34.49) - (143.11) |
(55.97) |
-882.8% |
Novavax Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
1,158.09 |
| Beta |
1.05 |
| Outstanding shares (mil) |
161.97 |
| Enterprise Value (mil) |
1,123.41 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.99% |
| Cost of Debt |
4.59% |
| WACC |
7.44% |